Adial Pharmaceuticals(ADIL)

POST3.970.000.00%16:10 EDT

3.97-0.02-0.50%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Adial Pharmaceuticals Delays Shareholder Meeting Vote on Proposals 3-6 to Oct. 15 Pending NASDAQ Approval
  Reuters · 10-03
  Adial Pharmaceuticals Delays Shareholder Meeting Vote on Proposals 3-6 to Oct. 15 Pending NASDAQ Approval
- Adial Pharmaceuticals Grants New-Hire Stock Option for 155,446 Shares at $4.22 Exercise Price
  Reuters · 10-01
  Adial Pharmaceuticals Grants New-Hire Stock Option for 155,446 Shares at $4.22 Exercise Price
- Adial Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  THOMSON REUTERS · 10-01
  Adial Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
  GlobeNewswire · 10-01
  Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Adial Pharmaceuticals Holds Annual Shareholder Meeting, Quorum Present
  Reuters · 09-19
  Adial Pharmaceuticals Holds Annual Shareholder Meeting, Quorum Present
- Adial Pharmaceuticals Amends Agreements to Restore Nasdaq Compliance
  TIPRANKS · 09-17
  Adial Pharmaceuticals Amends Agreements to Restore Nasdaq Compliance
- ADB Approves Rp11.5 Trillion Loan for Indonesia
  Tempo · 09-16
  ADB Approves Rp11.5 Trillion Loan for Indonesia
- Adial Pharmaceuticals files to sell 25.15M shares of common stock for holders
  TIPRANKS · 08-29
  Adial Pharmaceuticals files to sell 25.15M shares of common stock for holders
- Adial Pharmaceuticals - Proposed Resale of up to 25,148,970 Shares of Common Stock by Selling Stockholders - SEC Filing
  THOMSON REUTERS · 08-29
  Adial Pharmaceuticals - Proposed Resale of up to 25,148,970 Shares of Common Stock by Selling Stockholders - SEC Filing
- Adial Pharma Grants Unregistered Option for 307,814 Shares at $5.76 Per Share
  Reuters · 08-26
  Adial Pharma Grants Unregistered Option for 307,814 Shares at $5.76 Per Share
- Adial Pharmaceuticals Grants Inducement Stock Options to New Hire
  TIPRANKS · 08-26
  Adial Pharmaceuticals Grants Inducement Stock Options to New Hire
- Adial Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  THOMSON REUTERS · 08-26
  Adial Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
  GlobeNewswire · 08-26
  Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Adial Pharmaceuticals Announces Annual Shareholder Meeting
  Reuters · 08-25
  Adial Pharmaceuticals Announces Annual Shareholder Meeting
- Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
  TIPRANKS · 08-22
  Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
- Adial Pharmaceuticals Gets NASDAQ Notice for Falling Below $2.5 Million Stockholders’ Equity Minimum
  Reuters · 08-22
  Adial Pharmaceuticals Gets NASDAQ Notice for Falling Below $2.5 Million Stockholders’ Equity Minimum
- U.S. Stocks on the MOVE - Sunrun, JetBlue Airways, Dell Technologies
  Reuters · 08-17
  U.S. Stocks on the MOVE - Sunrun, JetBlue Airways, Dell Technologies
- U.S. Stocks on the MOVE - KBR, Vista Energy, Fulcrum Therapeutics
  Reuters · 08-17
  U.S. Stocks on the MOVE - KBR, Vista Energy, Fulcrum Therapeutics
- Adial Pharmaceuticals Q2 EPS $(11.25)
  Benzinga Earnings · 08-17
  Adial Pharmaceuticals Q2 EPS $(11.25)
- Adial Pharmaceuticals Falls After Quarterly Loss Widens
  Reuters · 08-17
  Adial Pharmaceuticals Falls After Quarterly Loss Widens
Company Profile
Company Name
Adial Pharmaceuticals
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.adial.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
- 10-02
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 09-18
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 09-16
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 08-28
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 08-25
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 08-21
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 08-17
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 08-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 08-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 08-11
  Major Issues Report
  Form 8-K/A - Current report: [Amend]
  Form 8-K/A - Current report: [Amend]
- 07-01
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 06-24
  Beneficial Ownership Change
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
- 06-11
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-11
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report

1D
5D
Day
Week
Month

Loading ...

High

4.05

Open

4.02

Volume%

0.16

Low

3.92

3.99

T/O Rate

0.20%

To The Moon

Adial Pharmaceuticals(ADIL)

Company Profile

Most Discussed